Helsinn signs agreements with Blanver and Varifarma
September 2, 2019
Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, together with Blanver Farmoquímica e Farmacêutica S.A., and Laboratorio Varifarma, today announce they have signed exclusive distribution and licensing agreements for Pracinostat in South America.
Pracinostat is an oral HDAC that is in a pivotal Phase III study in combination with Azacitidine for the treatment of adults with newly diagnosed acute myeloid leukemia (“AML”) who are unfit for intensive induction chemotherapy. It is also being evaluated in a Phase II study in patients with high risk myelodysplastic syndromes (“MDS”).
“It is a great satisfaction for Varifarma to have been chosen to represent Helsinn and its product Pracinostat, for Argentina, Bolivia, Chile, Colombia, Ecuador, Paraguay, Peru and Uruguay. We take this challenge with great commitment and the responsibility we use to work with. Sharing the same values and ethics, we look forward to start a successful venture together providing care and novel products to more patients in our region.”
Marcelo Conti, Laboratorio Varifarma Director
